Literature DB >> 10820270

Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection.

G M Monteforte1, K Takeda, M Rodriguez-Sosa, S Akira, J R David, A R Satoskar.   

Abstract

IL-18 has been shown to play a critical role in the development of a Th1 response and immunity against intracellular pathogens. To determine the role of IL-18 in the development of protective immunity against Leishmania major, we have analyzed the course of cutaneous L. major in IL-18-deficient C57BL/6 mice (IL-18-/-) compared with similarly infected wild-type mice (IL-18+/+). After L. major infection, IL-18-/- mice may develop larger lesions during early phase of infection but eventually will resolve them as efficiently as IL-18+/+ mice. By 2 wk after infection, although Ag-stimulated lymph node cells from L. major-infected IL-18+/+ and IL-18-/- mice produced similar levels of IFN-gamma, those from IL-18-/- mice produced significantly more IL-12 and IL-4. By 10 wk after infection, both IL-18+/+ and IL-18-/- mice had resolved L. major infection. At this time, lymph node cells from both IL-18+/+ and IL-18-/- mice produced IL-12 and IFN-gamma but no IL-4. Furthermore, administration of anti-IFN-gamma Abs to IL-18-/- mice rendered them susceptible to L. major. These results indicate that despite the role IL-18 may play in early control of cutaneous L. major lesion growth, this cytokine is not critical for development of protective Th1 response and resolution of L. major infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820270     DOI: 10.4049/jimmunol.164.11.5890

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 2.  NLR proteins and parasitic disease.

Authors:  Gwendolyn M Clay; Fayyaz S Sutterwala; Mary E Wilson
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

3.  Do you see what I see: Recognition of protozoan parasites by Toll-like receptors.

Authors:  Debopam Ghosh; Jason S Stumhofer
Journal:  Curr Immunol Rev       Date:  2013-08

Review 4.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

5.  High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmania major are interleukin-4 dependent.

Authors:  Andrea Debus; Joachim Gläsner; Martin Röllinghoff; André Gessner
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 6.  Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors.

Authors:  Prajwal Gurung; Thirumala-Devi Kanneganti
Journal:  Cell Mol Life Sci       Date:  2016-03-31       Impact factor: 9.261

7.  MyD88 negatively controls hypergammaglobulinemia with autoantibody production during bacterial infection.

Authors:  Anne Woods; Pauline Soulas-Sprauel; Benoit Jaulhac; Bérénice Arditi; Anne-Marie Knapp; Jean-Louis Pasquali; Anne-Sophie Korganow; Thierry Martin
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

Review 8.  Innate immunity against Leishmania infections.

Authors:  Prajwal Gurung; Thirumala-Devi Kanneganti
Journal:  Cell Microbiol       Date:  2015-08-11       Impact factor: 3.715

9.  Endogenous interleukin-12 is critical for controlling the late but not the early stage of Leishmania mexicana infection in C57BL/6 mice.

Authors:  Fabiola Aguilar Torrentera; Jon D Laman; Marjan Van Meurs; Luciano Adorini; Eric Muraille; Y Carlier
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 10.  How Inflammasomes Inform Adaptive Immunity.

Authors:  Charles L Evavold; Jonathan C Kagan
Journal:  J Mol Biol       Date:  2017-10-05       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.